Direkt zum Inhalt
Merck

A7856

Sigma-Aldrich

Acipimox

≥99% (TLC)

Synonym(e):

2-Carboxy-5-methylpyrazine 4-oxide, 5-Methylpyrazinecarboxylic acid 4-oxide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C6H6N2O3
CAS-Nummer:
Molekulargewicht:
154.12
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
12352205
NACRES:
NA.79

Qualitätsniveau

Assay

≥99% (TLC)

Form

powder

Farbe

off-white to faint yellow

mp (Schmelzpunkt)

177-180 °C

Lagertemp.

2-8°C

SMILES String

[n+]1(c(cncc1C(=O)O)C)[O-]

InChI

1S/C6H6N2O3/c1-4-2-7-3-5(6(9)10)8(4)11/h2-3H,1H3,(H,9,10)

InChIKey

DNRXJHATQULEHC-UHFFFAOYSA-N

Biochem./physiol. Wirkung

Acipimox, also known as olbemox, is a nicotinic acid analog. It functions as an anti-lipolytic drug and vasodilator. Acipimox may be used in various metabolic studies involving insulin and ghrelin. It lowers total cholesterol and total triglycerides, which helps in the treatment of hyperlipidemia.
Niacin-derived, vasodilator studied for its lipid-lowering effect.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Hanna-Riikka Lehto et al.
The Journal of clinical endocrinology and metabolism, 97(9), 3277-3284 (2012-07-05)
We tested the hypothesis that a persistent reduction in free fatty acid (FFA) levels improves cardiac function and systemic insulin sensitivity via a reduction in the myocardial and skeletal muscle adiposities and a modulation in adipokine release. Study subjects (body
J Huang et al.
Drug research, 63(2), 79-83 (2013-03-01)
The study was designed to compare the pharmacokinetic parameters and relative bioavailability of a newly generic acipimox 250-mg tablets (test formulation) with a branded 250-mg tablets (reference formulation). A single-dose, randomized-sequence, 2-way crossover study was conducted in 20 healthy Chinese
Feipeng Jin et al.
Biochemical and biophysical research communications, 428(1), 86-92 (2012-10-13)
Saturated fatty acids (FA) have been linked to an increased risk of cardiovascular disease. The effects of acipimox, a FA-lowering agent, on palmitate- (an important saturated fatty acid) stimulated atherosclerosis remains to be elucidated. We investigated the effects of acipimox
Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia
Taskinen MR and Nikkila EA
Atherosclerosis, 69(2-3), 249-255 (1988)
Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Vaag A, et al.
The Journal of Clinical Investigation, 88(4), 1282-1290 (1991)

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.